CureVac - Ingmar Hoerr, CEO

Đã xem số lần 1,217

Thẩm định con người

8.1
Cảm ơn bạn! Bình chọn của bạn đã được ghi lại và hiển thị sớm
Không
Bổ sung vào danh sách đánh dấu của bạn
Miêu tả:

CureVac, a clinical stage biopharmaceutical company from Tübingen, Germany, is pioneering the field of mRNA-based technology platforms for medical purposes with which mRNA is specifically optimised and formulated. Since 2000 the company develops novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases – both under the brand RNActive®. CureVac has successfully established the first GMP (good manufacturing practice) facility worldwide for the manufacture of RNA and mRNA and has pioneered mRNA-based drugs in clinical studies.

Bình luận